# Earnings Review Briefs - February 2026
**Prepared:** 2026-01-31
**Analyst:** Review Agent (investment-domain)
**Status:** Pre-earnings analysis for 3 active positions

---

## POSITION 1: Pfizer (PFE) - Q4 2025 Earnings

**Earnings Date:** Monday, February 3, 2026 (before market open)
**Current Position:** 18.66 shares, $499 invested, current value $493 (-1.2%)
**Thesis:** Defensive pharma, 6.6% dividend yield, pipeline optionality

### Consensus Estimates

| Metric | Estimate | YoY Change | Notes |
|--------|----------|------------|-------|
| **EPS** | $0.57 | -9.5% | Range $0.56-$0.58 across sources |
| **Revenue** | Lower YoY | Decline expected | Specific revenue estimate not disclosed |
| **Estimate Trend** | -1.97% (30d) | Downward | Analysts becoming more cautious |

**Beat History:** 4 consecutive quarters of EPS beats. Last quarter: $0.87 actual vs $0.66 consensus (+32%).

### Key Metrics to Watch

1. **COVID Revenue Decline Rate**
   - Critical: Rate of decline vs guidance
   - Framework: Faster decline = worse, but expected
   - Trigger: If COVID products drop >50% YoY sequentially, signals faster-than-expected erosion

2. **Pipeline Progress - Obesity**
   - Metsera acquisition ($10B, Nov 2025): Any integration updates
   - MET-097i (phase 2 completed "with flying colors"): Timeline to phase 3
   - YP05002 (oral GLP-1): Development milestones
   - **15 new obesity trials starting 2026** - most phase 3 from Metsera
   - Trigger: Delay in phase 3 trials = negative

3. **Pipeline Progress - Oncology**
   - Vepdegestrant (ER+/HER2- breast cancer): PROTAC, late-stage
   - Atirmociclib (CDK4 inhibitor): 1st line HR+/HER2-
   - Sigvotatug vedotin (ADC for NSCLC): Update expected
   - Q1-Q3 2025: Oncology sales +20.6% operationally to $18.52B
   - Trigger: 2026 oncology guidance <4% growth = disappointing

4. **2026 Full-Year Guidance**
   - Consensus 2026 EPS: $3.04 (down from $3.15 60 days ago)
   - Company guided: $2.80-$3.00 (below consensus)
   - Trigger: Guide below $2.80 = major concern

5. **Dividend Safety**
   - Current yield: 6.6%
   - Watch: FCF coverage, commentary on dividend policy
   - Trigger: Any language suggesting dividend review = sell signal

### Key Risks This Quarter

1. **Patent Cliff Acceleration:** Eliquis, Ibrance LOE approaching. Management must articulate replacement revenue path.
2. **2026 Guidance Miss:** Already guided below consensus. Further reduction would be severe negative.
3. **Obesity Program Delays:** Market has priced in Metsera success. Any setback = immediate re-rate.
4. **Cost Overruns:** Recent acquisitions (Seagen $43B, Metsera $10B). Integration costs could pressure margins.

### Decision Framework

| Scenario | EPS vs Est | Revenue Trend | Pipeline | Guidance | Decision |
|----------|-----------|---------------|----------|----------|----------|
| **BULL** | Beat >$0.60 | Stable ex-COVID | Obesity trial starts on track | Raise to $3.05+ | **ADD** if <$25 |
| **BASE** | $0.55-$0.59 | In-line | No major updates | Reaffirm $2.80-$3.00 | **HOLD** |
| **BEAR** | Miss <$0.55 | Worse than expected | Trial delays | Cut below $2.80 | **TRIM 50%** |

### Specific Triggers

**HOLD Confirmed IF:**
- EPS $0.55-$0.59 (in-line to slight miss acceptable)
- 2026 guidance reaffirmed at $2.80-$3.00
- Obesity trials on schedule (15 trials starting 2026)
- Oncology maintains 4% operational growth guidance
- Dividend explicitly reaffirmed

**ADD Consideration IF:**
- EPS >$0.60 (beat by >5%)
- 2026 guidance raised to $3.05+
- Major pipeline catalyst (FDA approval or breakthrough data)
- Price drops to $24-25 (current ~$26.40)

**TRIM 50% IF:**
- EPS <$0.55 (miss >3.5%)
- 2026 guidance cut below $2.80
- Obesity trial delays announced
- Any language suggesting dividend at risk
- Oncology growth outlook deteriorates

### Analyst Sentiment

- **Zacks Rank:** #3 (Hold)
- **Bullish View:** "Most intriguing value play of 2026" - oncology + obesity + cost cuts
- **Neutral View (Mizuho):** "OK considering variety of factors" - acknowledges headwinds
- **Consensus Trend:** Estimates declining (EPS down 3.5% in 60d)

### Pre-Earnings View

**Recommendation: HOLD**

**Rationale:**
1. Defensive position with 6.6% yield provides downside cushion
2. Already down -1.2%, minimal downside from current level
3. 4-quarter beat streak suggests guidance conservatism
4. Obesity pipeline de-risked via Metsera acquisition
5. Position size small (18.66 shares, ~10% of portfolio)

**Risk:** If Q4 disappoints AND 2026 guidance is cut, stock could drop to $23-24. This would trigger TRIM decision.

---

## POSITION 2: Allstate (ALL) - Q4 2025 Earnings

**Earnings Date:** Wednesday, February 5, 2026 (after market close, 4:15 PM ET)
**Conference Call:** Thursday, February 5, 2026
**Current Position:** 2.04 shares, $400 invested, current value $406 (+1.5%)
**Thesis:** Insurance hard market, combined ratio improvement, catastrophe normalization

### Consensus Estimates

| Metric | Estimate | YoY Change | Notes |
|--------|----------|------------|-------|
| **EPS** | $8.72-$9.53 | +13.7% to +24% | Range across sources |
| **Revenue** | $17.52B | -- | Consensus from Zacks |
| **P/L Combined Ratio** | 82.7% | -4.2 pts | vs 86.9% Q4 2024 |
| **Auto Combined Ratio** | 90.0% | -3.5 pts | vs 93.5% Q4 2024 |
| **Home Combined Ratio** | 64.1% | -5.7 pts | vs 69.8% Q4 2024 |

**Beat History:** 4 consecutive quarters of beats, average surprise +47.3%. Strong execution track record.

### Key Metrics to Watch

1. **Catastrophe Losses Q4 2025**
   - **Q4 2025 Actual:** $209M pre-tax ($165M after-tax)
   - **Comparison:** Down significantly from Q3 2025 (Q3 had $209M in Dec alone)
   - **Full Year 2024:** Combined ratio 94.3 vs 104.5 in 2023
   - **Trigger:** If Q4 CAT losses >$300M, could pressure combined ratio above 85%

2. **Property-Liability Combined Ratio**
   - **Q4 2025 Est:** 82.7% vs 86.9% Q4 2024
   - **Q3 2025 Actual:** 80.1 (-16.3 pts YoY due to low CATs)
   - **Framework:** <85% = excellent, 85-90% = good, >90% = concerning
   - **Trigger:** >85% would suggest underlying deterioration beyond CAT benefit

3. **Policies in Force (PIF) Growth**
   - Watch: Auto PIF, Home PIF
   - "Transformative Growth" program driving results
   - Trigger: Negative PIF growth in Auto = market share loss, concerning

4. **Investment Income**
   - Key to profitability given bond yields remained elevated
   - Watch: NII growth rate vs Q4 2024
   - Trigger: NII decline despite higher rates = portfolio issues

5. **2026 Full-Year Guidance**
   - Combined ratio target: Mid-90s for full year
   - Profit improvement sustainability
   - Trigger: 2026 combined ratio guide >95% = disappointing

### Key Risks This Quarter

1. **Catastrophe Normalization:** Q4 2025 CAT losses were exceptionally low ($209M). If 2026 guidance assumes this continues, it's too optimistic.
2. **Auto Insurance Competition:** Rate increases slowing, competition increasing. PIF growth could stall.
3. **Homeowners Margin Compression:** Climate risk = rising reinsurance costs. 64.1% combined ratio may not be sustainable.
4. **Reserve Releases:** Q3 2025 benefited from non-CAT reserve releases. If Q4 also relied on releases, underlying profitability may be weaker.

### Decision Framework

| Scenario | EPS vs Est | Combined Ratio | CAT Losses | 2026 Guide | Decision |
|----------|-----------|----------------|------------|------------|----------|
| **BULL** | Beat >$9.50 | <83% | <$250M | Mid-90s CR, profit growth | **ADD** if <$200 |
| **BASE** | $8.50-$9.50 | 83-85% | $200-300M | Mid-90s CR maintained | **HOLD** |
| **BEAR** | Miss <$8.50 | >85% | >$300M | 2026 CR guide >95% | **TRIM 50%** |

### Specific Triggers

**HOLD Confirmed IF:**
- EPS $8.50-$9.50 (in-line range)
- Combined ratio 82-85% (within target)
- CAT losses <$300M (normalized but not extreme)
- 2026 combined ratio guidance mid-90s
- PIF growth positive in Auto and Home

**ADD Consideration IF:**
- EPS >$9.50 (beat consensus)
- Combined ratio <83% (structural improvement evident)
- 2026 guidance suggests combined ratio trending to low-90s
- Price dips to $195-200 (current ~$199)
- Management increases buyback or dividend

**TRIM 50% IF:**
- EPS <$8.50 (meaningful miss)
- Combined ratio >85% (deterioration despite low CATs)
- CAT losses >$350M (unlucky quarter)
- 2026 combined ratio guide >96% (profit outlook dims)
- PIF growth negative (losing market share)

### Pre-Earnings Setup

**Known Positives:**
- Q4 2025 CAT losses were very low ($209M after-tax)
- Q3 2025 combined ratio was exceptional (80.1)
- Hard market in insurance continuing
- 4-quarter beat streak (+47% avg surprise)

**Known Negatives:**
- Low CAT losses may have pulled forward FY results
- Reinsurance costs rising (climate risk)
- Auto insurance rate increases moderating
- Comps get tougher (Q4 2024 CR was 86.9, not terrible)

### Analyst Sentiment

- Consensus improving: EPS up 13.7% to 24% YoY
- Combined ratio expectations aggressive (82.7% is very good)
- Recent monthly CAT data trending low (Feb 2025: $73M)

### Pre-Earnings View

**Recommendation: HOLD**

**Rationale:**
1. Setup is favorable: low Q4 CAT losses known, expectations moderate
2. Position already +1.5%, room to run if beats
3. Combined ratio improvement thesis intact
4. Small position (2.04 shares, ~8% of portfolio), low risk
5. Insurance hard market persists, pricing power remains

**Opportunity:** If stock dips on profit-taking pre-earnings to $195-197, consider small ADD.

**Risk:** If combined ratio disappoints (>85%) despite low CATs, suggests underlying deterioration. Would trigger TRIM.

---

## POSITION 3: Shell (SHEL) - Q4 2025 Earnings

**Earnings Date:** Wednesday, February 5, 2026
**Current Position:** 40.85 shares, $1,500 invested, current value $3,147 (+110%)
**Thesis:** Free cash flow machine, disciplined capital returns, energy transition hedge via LNG

**NOTE:** Shell pre-announced Q4 2025 results via update note on January 8, 2026. Results were soft but largely anticipated.

### Consensus Estimates

| Metric | Estimate | YoY Change | Notes |
|--------|----------|------------|-------|
| **EPS** | $1.24 | Decline expected | Wall Street consensus |
| **Adj EBITDA** | $56B | -$9.8B (-15%) | vs $65.8B Q4 2024 |
| **FCF (Q3 ref)** | $10.0B | -- | Q3 2025 actual |
| **CFO (Q3 ref)** | $12.2B | -- | Q3 2025 actual |

**Buyback Program:** $3.5B for Q4 2025 (16th consecutive quarter ≥$3B). Shareholder distributions = 48% of CFO (target: 40-50%).

### Key Metrics to Watch

1. **Free Cash Flow**
   - Q3 2025: $10.0B FCF
   - Framework: >$10B/quarter = strong, $8-10B = acceptable, <$8B = concerning
   - **Trigger:** FCF <$8B would raise questions about capital return sustainability

2. **Buyback Program Continuation**
   - Q4 2025: $3.5B executed
   - Watch: Q1 2026 buyback announcement (target ≥$3B)
   - **Trigger:** Buyback <$3B for Q1 2026 = negative signal on cash generation outlook

3. **Integrated Gas - LNG Trading**
   - Q4 2025 guidance: LNG volumes 7.5-7.9 MT
   - Trading expected "in-line with Q3 2025"
   - Integrated Gas production: 930-970 kboe/d
   - **Trigger:** LNG trading results "below Q3 2025" = margin pressure

4. **2026 Capex Guidance**
   - 2025-2028 framework: $20-22B annually (down from 2022 levels)
   - Allocation: $12-14B to Integrated Gas & Upstream, $8B to Downstream & Renewables
   - **Trigger:** Capex guide >$23B = capital discipline slipping

5. **Dividend Sustainability**
   - Current distribution: 48% of CFO (in target range 40-50%)
   - Watch: Any commentary on dividend policy
   - **Trigger:** Distribution ratio >50% or language suggesting dividend pressure = concern

### Pre-Announced Q4 2025 Results (Jan 8, 2026)

Shell issued a Q4 2025 update note warning of softer results:
- Integrated Gas production: 930-970 kboe/d (midpoint in-line)
- LNG liquefaction: 7.5-7.9 MT (in-line)
- Trading: Expected in-line with Q3
- Chemicals: Weaker segment (flagged)

**Market Reaction:** Stock likely priced in soft Q4. Focus shifts to 2026 outlook.

### Key Risks This Quarter

1. **Oil Price Weakness:** Brent averaged ~$75-80 in Q4 2025. If 2026 outlook assumes $70-75, FCF guide could disappoint.
2. **LNG Margin Compression:** Global LNG supply increasing (US, Qatar). Shell's trading margins could compress.
3. **Chemicals Weakness:** Already flagged as weak in Q4. If deterioration continues into 2026, headwind to earnings.
4. **Capex Creep:** Energy transition projects (renewables, biofuels) often exceed budgets. Watch for capex guide increases.
5. **Dividend Cut Risk (low but non-zero):** If oil averages <$70 in 2026, FCF may not support $3B+ quarterly buybacks + dividend.

### Decision Framework

| Scenario | FCF (Q4) | Buyback (Q1 2026) | LNG Trading | 2026 Capex | Decision |
|----------|---------|------------------|-------------|------------|----------|
| **BULL** | >$11B | $3.5B+ | Beat Q3 | $20-21B | **HOLD** (already +110%) |
| **BASE** | $9-11B | $3.0-3.5B | In-line Q3 | $21-22B | **HOLD** |
| **BEAR** | <$9B | <$3.0B | Below Q3 | >$22B | **TRIM 25-50%** |

### Specific Triggers

**HOLD Confirmed IF:**
- Q4 FCF $9-11B (in-line expectations post pre-announcement)
- Q1 2026 buyback ≥$3B (discipline maintained)
- LNG trading in-line or better than Q3 2025
- 2026 capex guidance $20-22B (within framework)
- Dividend + buybacks remain 40-50% of CFO

**TRIM 25% (Take Some Profit) IF:**
- Position >100% gain AND any of:
  - FCF <$9B
  - Q1 2026 buyback <$3B
  - 2026 capex guide >$23B
  - Oil price outlook for 2026 <$70 Brent

**TRIM 50% (Major Concern) IF:**
- FCF <$8B (structural deterioration)
- Buyback suspended or cut to <$2.5B
- Dividend language suggests pressure
- LNG trading significantly below Q3 2025
- Chemicals impairment announced

### Position Management Context

**Current Status:**
- **+110% gain** ($1,500 → $3,147)
- **Largest position** by absolute value ($3,147)
- **Risk:** Concentration + geopolitical (Europe energy, Russia/Ukraine)

**Strategic Considerations:**
1. **Profit-Taking Logic:** At +110%, taking 25-50% profit is defensible even if thesis intact. Reduces concentration risk.
2. **Tax Consideration:** If long-term capital gains, tax hit is manageable. If short-term, may prefer to wait.
3. **Redeployment:** Trimming Shell frees capital for higher-conviction ideas or rebalancing.

**Recommendation:** Given +110% gain, **consider 25% TRIM regardless of earnings** to lock profit and reduce concentration. Remaining 75% can ride on FCF thesis.

### Pre-Earnings View

**Recommendation: HOLD with 25% TRIM consideration**

**Rationale for HOLD:**
1. FCF generation remains strong ($10B/quarter in Q3)
2. Buyback discipline intact (16 consecutive quarters ≥$3B)
3. Energy transition via LNG is long-term positive
4. Dividend yield attractive (~3.5-4%)
5. Q4 soft results already pre-announced (priced in)

**Rationale for 25% TRIM:**
1. Position up +110%, de-risking is prudent
2. Concentration: largest position by value
3. Geopolitical risk (Europe energy security)
4. Oil price volatility (downside if Brent <$70)
5. Frees capital for redeployment

**Final View:** If Q4 FCF >$10B and Q1 2026 buyback ≥$3B, **HOLD remaining 75%**. If FCF <$9B or buyback cut, **TRIM another 25-50%**.

---

## Summary Decision Matrix

| Position | Earnings Date | Current Status | Base Case | Upside Scenario | Downside Scenario |
|----------|--------------|----------------|-----------|-----------------|-------------------|
| **PFE** | Mon Feb 3 | -1.2%, HOLD | EPS $0.57, guide reaffirmed → **HOLD** | EPS >$0.60, guide raised → **ADD** | EPS <$0.55, guide cut → **TRIM 50%** |
| **ALL** | Wed Feb 5 | +1.5%, HOLD | EPS $8.72, CR 83% → **HOLD** | EPS >$9.50, CR <83% → **ADD** | EPS <$8.50, CR >85% → **TRIM 50%** |
| **SHEL** | Wed Feb 5 | +110%, HOLD | FCF $9-11B, buyback $3B → **HOLD** | FCF >$11B, buyback $3.5B → **HOLD** (trim 25% for profit) | FCF <$9B, buyback <$3B → **TRIM 50%** |

---

## Post-Earnings Action Protocol

### Immediate (Within 24h of Earnings)
1. **Read full earnings release** + 10-K/10-Q filing (not just headlines)
2. **Listen to conference call** or read transcript (management tone, Q&A)
3. **Compare actuals to estimates** in this brief (document variances)
4. **Check thesis file** (thesis/active/{TICKER}/) - does thesis still hold?

### Within 3 Days
1. **Write earnings review** → journal/reviews/{date}_{TICKER}_review.md
2. **Update investment committee** if decision changes (HOLD → TRIM or ADD)
3. **Execute trades** (if approved by human/portfolio owner)
4. **Update portfolio/current.yaml** post-trade

### Red Flags Requiring Immediate Escalation
- Dividend cut or suspension (any position)
- Guidance cut >10% (any position)
- Accounting irregularity mentioned
- CFO/CEO departure announced
- Major litigation disclosed
- Debt covenant concern raised

---

## Data Sources & Validation

**Price Data:** Via yfinance (tools/price_checker.py) - NEVER use WebSearch for prices
**Estimates:** Cross-referenced Nasdaq, TipRanks, Zacks, Yahoo Finance
**Company Guidance:** Official investor relations, SEC filings
**Analyst Commentary:** Seeking Alpha, Yahoo Finance, TipRanks

**Validation:**
- EPS estimates validated across 3+ sources (range: ±$0.02 variance acceptable)
- Combined ratio estimates from analyst consensus (Zacks primary source)
- FCF/buyback data from Shell investor relations and quarterly updates
- All material facts footnoted with source

**Discrepancies Noted:**
- Pfizer Q4 EPS: Range $0.56-$0.58 (used $0.57 midpoint)
- Allstate Q4 EPS: Range $8.72-$9.53 (wide range, used conservative $8.72)
- Shell Q4 EBITDA: Only one source ($56B consensus), could not validate elsewhere

---

## Analyst Notes

**Prepared by:** Review Agent (sub-agent of investment-domain)
**Skills Used:** investment-rules, critical-thinking
**Cross-Check:** fundamental-analyst (thesis validation), portfolio-domain (position sizing)

**Autocrítica:**
- **Asunciones:** All estimates assume analysts have correctly modeled. Analysts often miss on pharma pipelines (Pfizer) and CAT losses (Allstate).
- **Sesgos detectados:** Anchoring bias on recent performance (Allstate 4-quarter beat streak may create false confidence).
- **Evidencia ignorada:** Did not model scenario where multiple positions disappoint simultaneously (correlation risk if market sells off).
- **Validación:** Cross-referenced 3+ sources for estimates. Shell Q4 data relies on company pre-announcement (high confidence).
- **Alternativas consideradas:** Considered full exit on Shell (+110%) but FCF thesis still intact, so partial trim preferred.

**Risk Disclosure:**
- Analyst estimates are often wrong (average error ±5-10% on EPS)
- Management guidance is systematically optimistic (discount 20-30% per investment-rules)
- Macro shocks (geopolitical, Fed policy) can override fundamentals
- This analysis assumes no black swan events (pandemic, war, financial crisis)

**Confidence Levels:**
- **PFE:** Medium confidence (earnings volatile, pipeline binary)
- **ALL:** High confidence (CAT losses known, hard market intact)
- **SHEL:** High confidence (Q4 pre-announced, buyback discipline strong)

---

**NEXT STEPS:**
1. Monitor earnings releases Feb 3-5
2. Prepare rapid response reviews post-earnings
3. Escalate to investment-committee if any position triggers TRIM or ADD
4. Update portfolio/current.yaml only after human approval

**END BRIEF**

---

## Sources

### Pfizer (PFE)
- [Nasdaq PFE Earnings Forecasts](https://www.nasdaq.com/market-activity/stocks/pfe/earnings)
- [Pfizer 2026 Guidance Press Release](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides)
- [Yahoo Finance PFE Analysis](https://finance.yahoo.com/quote/PFE/analysis/)
- [MarketBeat PFE Earnings](https://www.marketbeat.com/stocks/NYSE/PFE/earnings/)
- [Nasdaq Earnings Preview: PFE Q4](https://www.nasdaq.com/articles/earnings-preview-pfizer-pfe-q4-earnings-expected-decline)
- [Seeking Alpha: Pfizer Value Play 2026](https://seekingalpha.com/article/4860110-pfizer-the-most-intriguing-value-play-of-2026)
- [Pfizer 2026 Pipeline Catalysts](https://www.pfizer.com/pfizer-pipeline-key-anticipated-2026-catalysts)
- [CNBC: Pfizer 2026 Outlook](https://www.cnbc.com/2025/12/16/pfizer-2026-guidance-metsera-seagen-deals.html)

### Allstate (ALL)
- [Yahoo Finance: Allstate Q4 Earnings Preview](https://finance.yahoo.com/news/curious-allstate-q4-performance-explore-141507189.html)
- [TipRanks Allstate Earnings](https://www.tipranks.com/stocks/all/earnings)
- [Allstate Investor Relations - Quarterly Results](https://www.allstateinvestors.com/financials/quarterly-results)
- [Nasdaq ALL Earnings Forecasts](https://www.nasdaq.com/market-activity/stocks/all/earnings)
- [Morningstar: Allstate Q3 2025 Results](https://www.morningstar.com/news/business-wire/20251105652237/allstate-reports-third-quarter-2025-results)
- [Insurance Journal: Allstate Q4 Income](https://www.insurancejournal.com/news/national/2025/02/05/810958.htm)

### Shell (SHEL)
- [TipRanks Shell Earnings](https://www.tipranks.com/stocks/shel/earnings)
- [Shell Q4 2025 Update Note (PDF)](https://www.shell.com/news-and-insights/newsroom/news-and-media-releases/2026/shell-fourth-quarter-2025-update-note/)
- [Nasdaq SHEL Earnings Forecasts](https://www.nasdaq.com/market-activity/stocks/shel/earnings)
- [Shell Results and Reporting](https://www.shell.com/investors/results-and-reporting.html)
- [Shell LNG Outlook 2025](https://www.shell.com/what-we-do/oil-and-natural-gas/liquefied-natural-gas-lng/lng-outlook-2025.html)
- [Shell Financial Modelling Guidance Oct 2025](https://www.shell.com/investors/results-and-reporting/data-supplements/)
